DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cyclophosphamide (Cyclophosphamide) - Death - Suspected Cause - Side Effect Reports

 
 



Index of reports > Death (1301)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cyclophosphamide death. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 1301   Next >>

Possible Cyclophosphamide side effects in 57 year old female

Reported by a physician from Croatia (Local Name: Hrvatska) on 2012-08-27

Patient: 57 year old female

Reactions: Breast Cancer Metastatic, Paraneoplastic Dermatomyositis, Pulmonary Embolism

Adverse event resulted in: death

Drug(s) suspected as cause:
Capecitabine
    Administration route: Oral
    Indication: Breast Cancer

Cisplatin
    Dosage: 6 cycles
    Indication: Breast Cancer

Cyclophosphamide
    Dosage: 6 cycles
    Indication: Breast Cancer

Doxorubicin Hydrochloride
    Dosage: 6 cycles
    Indication: Breast Cancer

Gemcitabine Hydrochloride
    Indication: Breast Cancer

Paclitaxel
    Indication: Breast Cancer



Possible Cyclophosphamide side effects in 49 year old male

Reported by a physician from Norway on 2012-08-27

Patient: 49 year old male

Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Lung Infiltration, Septic Shock, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: on day 8
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: for escalated cycles on day 1
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: for standard cycles on day 1

Doxorubicin Hydrochloride
    Dosage: for escalated cycles on day 1
    Indication: Hodgkin's Disease

Doxorubicin Hydrochloride
    Dosage: on day 1,for standard cycles

Etoposide
    Dosage: for the escalated cycles on day 1 to 3

Etoposide
    Dosage: for the escalated cycles on day 1 to 3

Etoposide
    Dosage: for the standard cycles, day 1 to 3
    Indication: Hodgkin's Disease

Prednisolone
    Dosage: on day 1 to 14 every 21 day cycle treatment for 6 cycles
    Administration route: Oral
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: day 1 to 7
    Administration route: Oral
    Indication: Hodgkin's Disease

Vincristine
    Dosage: on day 8
    Indication: Hodgkin's Disease



Possible Cyclophosphamide side effects in 49 year old male

Reported by a physician from Norway on 2012-08-27

Patient: 49 year old male

Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Septic Shock, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: 10000 iu, day 8 (2 escalated cycles)
    Indication: Hodgkin's Disease

Bleomycin Sulfate
    Dosage: 10000 iu, day 8 (4 standard cycles)

Cyclophosphamide
    Dosage: 650 mg/m2, day 1 (4 standard cycles)

Cyclophosphamide
    Dosage: 1250 mg/m2, day 1 (2 escalated cycles)
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 25 mg/m2, day 1 (4 standard cycles)

Doxorubicin HCL
    Dosage: 35 mg/m2, day 1 (2 escalated cycles)
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 100 mg/m2, day 1-3 (4 standard cycles)

Etoposide
    Dosage: 200 mg/m2, day 1-3 (2 escalated cycles)
    Indication: Hodgkin's Disease

Prednisolone
    Dosage: 40 mg/m2, day 1-14 (4 standard cycles)
    Administration route: Oral

Prednisolone
    Dosage: 40 mg/m2, day 1-14 (2 escalated cycles)
    Administration route: Oral
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: 100 mg/m2, day 1-7 (2 escalated cycles)
    Administration route: Oral
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: 100 mg/m2, day 1-7 (4 standard cycles)
    Administration route: Oral

Vincristine
    Dosage: 1.4 mg/m2, day 8 (2 escalated cycles)
    Indication: Hodgkin's Disease

Vincristine
    Dosage: 1.4 mg/m2, day 8 (4 standard cycles)



Possible Cyclophosphamide side effects in male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-24

Patient: male, weighing 103.1 kg (226.8 pounds)

Reactions: Plasmacytosis, Pneumonia, Mouth Haemorrhage, Pseudomonas Infection, Headache, Disease Progression, Death, Mucosal Inflammation, Pleural Effusion, Depressed Level of Consciousness, Abscess, Lethargy, RIB Fracture

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cisplatin
    Indication: Multiple Myeloma

Cyclophosphamide
    Indication: Multiple Myeloma

Dexamethasone
    Indication: Multiple Myeloma

Doxorubicin Hydrochloride
    Indication: Multiple Myeloma

Etoposide
    Indication: Multiple Myeloma

Radiation Therapy NOS
    Indication: Multiple Myeloma

Revlimid
    Indication: Multiple Myeloma

Thalidomide
    Indication: Multiple Myeloma

Velcade
    Indication: Multiple Myeloma

Other drugs received by patient: Bendamustine Hydrochloride; Lenalidomide



Possible Cyclophosphamide side effects in 49 year old male

Reported by a physician from Norway on 2012-08-24

Patient: 49 year old male

Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Lung Infiltration, Septic Shock, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: on day 8
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: for escalated cycles on day 1
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: for standard cycles on day 1

Doxorubicin Hydrochloride
    Dosage: on day 1,for standard cycles

Doxorubicin Hydrochloride
    Dosage: for escalated cycles on day 1
    Indication: Hodgkin's Disease

Etoposide
    Dosage: for the escalated cycles on day 1 to 3

Etoposide
    Dosage: for the escalated cycles on day 1 to 3

Etoposide
    Dosage: for the standard cycles, day 1 to 3
    Indication: Hodgkin's Disease

Prednisolone
    Dosage: on day 1 to 14 every 21 day cycle treatment for 6 cycles
    Administration route: Oral
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: day 1 to 7
    Administration route: Oral
    Indication: Hodgkin's Disease

Vincristine
    Dosage: on day 8
    Indication: Hodgkin's Disease



Possible Cyclophosphamide side effects in female

Reported by a physician from Bulgaria on 2012-08-24

Patient: female, weighing 63.0 kg (138.6 pounds)

Reactions: Circulatory Collapse, Bone Marrow Failure

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1000 milligram
    Indication: Multiple Myeloma
    Start date: 2012-05-23
    End date: 2012-05-25

Dexamethasone
    Dosage: 40 milligram
    Start date: 2012-06-02
    End date: 2012-06-05

Dexamethasone
    Dosage: 40 milligram
    Indication: Multiple Myeloma
    Start date: 2012-05-23
    End date: 2012-05-26

Dexamethasone
    Dosage: 20 milligram
    Start date: 2012-05-16
    End date: 2012-05-19

Doxorubicin Hydrochloride
    Dosage: 80 milligram
    Indication: Multiple Myeloma
    Start date: 2012-05-26
    End date: 2012-05-26

Revlimid
    Dosage: 25 milligram
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2012-05-30
    End date: 2012-06-07

Vincristine
    Dosage: 2 milligram
    Indication: Multiple Myeloma
    Start date: 2012-05-26
    End date: 2012-06-02

Other drugs received by patient: Milgamma; Dopamine HCL; Nexium; Atropine; Sodium Carbonate; Lyrica; Uromithexane; Electrolyte Infusions; Sodium Bicarbonate; Probitor; Tevagrastim



Possible Cyclophosphamide side effects in female

Reported by a physician from Thailand on 2012-08-24

Patient: female, weighing 57.4 kg (126.3 pounds)

Reactions: Neutropenia

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Doxorubicin Hydrochloride
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Mabthera
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Prednisone TAB
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Vincristine
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Other drugs received by patient: Dexamethasone; Acetaminophen; Ondansetron; Metformin HCL; Ondansetron; Ondansetron; Atenolol; Simvastatin; Benadryl



Possible Cyclophosphamide side effects in 52 year old female

Reported by a health professional (non-physician/pharmacist) from France on 2012-08-23

Patient: 52 year old female

Reactions: Neoplasm Malignant, Acute Myeloid Leukaemia

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 6 courses at 500 mg/m2 (cumulative dose : 3000 mg/m2)
    Indication: Breast Cancer
    Start date: 1991-01-01
    End date: 1991-01-01

Fluorouracil
    Dosage: 6 courses at 500 mg/m2 m2 (cumulative dose : 3000 mg/m2)
    Indication: Breast Cancer
    Start date: 1991-01-01
    End date: 1991-01-01

Novantrone
    Dosage: 6 courses
    Indication: Breast Cancer
    Start date: 1991-01-01
    End date: 1991-01-01



Possible Cyclophosphamide side effects in male

Reported by a physician from United States on 2012-08-23

Patient: male

Reactions: Death, Chalazion

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Multiple Myeloma

Dexamethasone
    Indication: Multiple Myeloma

Lenalidomide
    Indication: Multiple Myeloma

Velcade
    Dosage: 2 mg, 1/week
    Indication: Multiple Myeloma
    Start date: 2009-08-13
    End date: 2012-01-03

Other drugs received by patient: Bisphosphonates; Travoprost



Possible Cyclophosphamide side effects in 49 year old male

Reported by a physician from Norway on 2012-08-23

Patient: 49 year old male

Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Septic Shock, Lung Infiltration

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Baxter 15 000 IE Lyofilisat TIL Injeksjonsv?ske / Infusjonsv?s

Cyclophosphamide

Cyclophosphamide

Doxorubicin Hydrochloride

Doxorubicin Hydrochloride

Etoposide

Etoposide

Prednisolone
    Administration route: Oral

Procarbazine Hydrochloride
    Administration route: Oral

Vincristine



Possible Cyclophosphamide side effects in 51 year old male

Reported by a physician from Japan on 2012-08-22

Patient: 51 year old male, weighing 57.7 kg (126.9 pounds)

Reactions: Hypophosphataemia, Tumour Lysis Syndrome, Gastrointestinal Haemorrhage, Metabolic Acidosis, Hyperphosphataemia, Disseminated Intravascular Coagulation

Adverse event resulted in: death

Drug(s) suspected as cause:
Allopurinol
    Dosage: 300 mg, unk

Allopurinol
    Dosage: 200 mg, unk
    Indication: Tumour Lysis Syndrome

Cyclophosphamide
    Dosage: 1200 mg, unk
    Indication: Lymphoma

Doxorubicin HCL
    Dosage: 80 mg, unk
    Indication: Lymphoma

Methylprednisolone
    Dosage: 250 mg/day
    Indication: Lymphoma

Methylprednisolone
    Dosage: 60 mg/day

Sodium Bicarbonate
    Indication: Metabolic Acidosis

Vincristine
    Dosage: 2 mg, unk
    Indication: Lymphoma



Possible Cyclophosphamide side effects in male

Reported by a physician from United States on 2012-08-22

Patient: male

Reactions: Rectal Haemorrhage, Constipation, Cardiac Disorder, Hospitalisation, Granulocytopenia, Inappropriate Antidiuretic Hormone Secretion, Thrombocytopenia, Cardiac Failure Congestive, Pneumonia, Anaemia, Pancytopenia, Atrial Fibrillation, Febrile Neutropenia, Syncope, Embolism, Sepsis, Dehydration, Asthenia, Mantle Cell Lymphoma Recurrent, Leukopenia, Deep Vein Thrombosis, Infection

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1
    Indication: Mantle Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: Mantle Cell Lymphoma

Leukine
    Dosage: on day 9-15; 250 mcg/m2/day
    Indication: Mantle Cell Lymphoma

Leukine
    Dosage: on day 9-15; 250 mcg/m2/day
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Indication: Mantle Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: on day 15; as infusion
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: on day 15; as infusion
    Indication: Mantle Cell Lymphoma

Vincristine
    Dosage: on day 1 (maximum dose: 2mg)
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: on day 1 (maximum dose: 2mg)
    Indication: Mantle Cell Lymphoma



Possible Cyclophosphamide side effects in male

Reported by a consumer/non-health professional from Germany on 2012-08-21

Patient: male, weighing 86.0 kg (189.2 pounds)

Reactions: Pneumonia, Pulmonary Embolism, Cytomegalovirus Infection, Pulmonary Infarction, Lymphoma, Staphylococcal Sepsis

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1500 mg, qd (day 1)
    Indication: T-Cell Lymphoma
    Start date: 2009-12-07
    End date: 2010-01-11

Doxorubicin HCL
    Dosage: 100 mg, qd (day 1)
    Indication: T-Cell Lymphoma
    Start date: 2009-12-07
    End date: 2010-01-11

Filgrastim
    Dosage: 48 unk, qd (day 1)
    Indication: T-Cell Lymphoma
    Start date: 2009-12-25
    End date: 2010-01-15

Mabcampath
    Dosage: 30 mg, day 4 and 5 of each cycle 1-3
    Indication: T-Cell Lymphoma
    Start date: 2009-12-10
    End date: 2010-01-15

Prednisone
    Dosage: 10 mg, qd (day 1-5)
    Administration route: Oral
    Indication: T-Cell Lymphoma
    Start date: 2009-11-27
    End date: 2010-01-10

Vincristine
    Dosage: 1 mg, qd (day 1)
    Indication: T-Cell Lymphoma
    Start date: 2009-11-26
    End date: 2010-01-11

Other drugs received by patient: Torsemide; Metoprolol Succinate; Heparin; Marcumar; Pantoprazole; Sulfamethoprim



Possible Cyclophosphamide side effects in 45 year old female

Reported by a physician from United States on 2012-08-21

Patient: 45 year old female

Reactions: Epstein-Barr Virus Infection, Splenic Infection Fungal, Mycosis Fungoides Refractory, Granuloma, Pneumonia Cytomegaloviral

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Campath
    Dosage: unk
    Indication: Mycosis Fungoides
    Start date: 2006-06-01

Cisplatin
    Dosage: unk
    Indication: Mycosis Fungoides

Cyclophosphamide
    Dosage: unk
    Indication: Mycosis Fungoides
    Start date: 2006-01-01

Daunorubicin HCL
    Dosage: unk
    Indication: Mycosis Fungoides
    Start date: 2006-01-01

Dexamethasone
    Dosage: unk
    Indication: Mycosis Fungoides

Etoposide
    Dosage: unk
    Indication: Mycosis Fungoides

Fludara
    Dosage: 2 cycles
    Indication: Mycosis Fungoides

Ifosfamide
    Dosage: unk
    Indication: Mycosis Fungoides

Prednisone
    Dosage: unk
    Indication: Mycosis Fungoides
    Start date: 2006-01-01

Vincristine
    Dosage: unk
    Indication: Mycosis Fungoides
    Start date: 2006-01-01



Possible Cyclophosphamide side effects in 77 year old male

Reported by a health professional (non-physician/pharmacist) from China on 2012-08-21

Patient: 77 year old male

Reactions: Adverse Drug Reaction, Diffuse Large B-Cell Lymphoma

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Dexamethasone
    Dosage: in cycle 1
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Methotrexate
    Dosage: in cycle 1
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone
    Dosage: on days 1 to 5
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma



Possible Cyclophosphamide side effects in male

Reported by a physician from United States on 2012-08-21

Patient: male, weighing 115.7 kg (254.5 pounds)

Reactions: Gastrointestinal Haemorrhage, Cholecystitis Acute, T-Cell Lymphoma, Disseminated Intravascular Coagulation, Pancytopenia, Atrial Fibrillation, Multi-Organ Failure, Sepsis, Acute Respiratory Distress Syndrome

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Adriamycin PFS
    Indication: T-Cell Lymphoma
    Start date: 2006-09-10

Cyclophosphamide
    Indication: T-Cell Lymphoma
    Start date: 2006-01-01

Prednisone TAB
    Indication: T-Cell Lymphoma
    Start date: 2006-01-01

Remicade
    Dosage: 3 dose induction followed by maint. q 8 weeks, 300 mg on 29-jun-2006, total 27 infusions
    Indication: Rheumatoid Arthritis
    Start date: 2001-10-01
    End date: 2006-06-29

Vincristine
    Indication: T-Cell Lymphoma
    Start date: 2006-09-10

Other drugs received by patient: Azulfadine; Lisinopril



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-20

Patient:

Reactions: Death, Lymphoma, Diffuse Large B-Cell Lymphoma

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Prednisolone
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma



Possible Cyclophosphamide side effects in 51 year old male

Reported by a physician from Japan on 2012-08-20

Patient: 51 year old male

Reactions: Hypophosphataemia, Metabolic Acidosis, Tumour Lysis Syndrome, Gastrointestinal Haemorrhage, Hyperphosphataemia, Disseminated Intravascular Coagulation

Adverse event resulted in: death

Drug(s) suspected as cause:
Allopurinol
    Dosage: unk

Cyclophosphamide
    Dosage: 1200 mg, unk
    Indication: Lymphoma

Doxorubicin
    Dosage: 80 mg, unk
    Indication: Lymphoma

Methylprednisolone
    Dosage: 60 mg/day

Methylprednisolone
    Dosage: 250 mg/day
    Indication: Lymphoma

Sodium Bicarbonate
    Indication: Metabolic Acidosis

Vincristine
    Dosage: 2 mg, unk
    Indication: Lymphoma



Possible Cyclophosphamide side effects in female

Reported by a physician from Sweden on 2012-08-20

Patient: female

Reactions: Nausea, Progressive Multifocal Leukoencephalopathy, Hepatic Enzyme Increased

Adverse event resulted in: death

Drug(s) suspected as cause:
Azathioprine
    Dosage: 150 mg/day
    Administration route: Oral
    Indication: Polymyositis

Cyclophosphamide
    Dosage: 100 mg/day
    Administration route: Oral
    Indication: Polymyositis

Methotrexate
    Dosage: 20 mg/week
    Indication: Polymyositis

Methylprednisolone

Prednisone
    Dosage: 10mg daily

Prednisone
    Dosage: 17.5 mg/day
    Administration route: Oral

Prednisone
    Dosage: 60 mg/day

Prednisone
    Dosage: 2.5 mg/day

Prednisone
    Dosage: 40 mg/day
    Indication: Polymyositis



Possible Cyclophosphamide side effects in female

Reported by a physician from Sweden on 2012-08-20

Patient: female

Reactions: Nausea, Progressive Multifocal Leukoencephalopathy, Hepatic Enzyme Increased

Adverse event resulted in: death

Drug(s) suspected as cause:
Azathioprine
    Dosage: 150 mg/day
    Administration route: Oral
    Indication: Polymyositis

Cyclophosphamide
    Dosage: 100 mg/day
    Administration route: Oral
    Indication: Polymyositis

Methotrexate
    Dosage: 20 mg/week
    Indication: Polymyositis

Methylprednisolone

Prednisone
    Dosage: 40 mg/day
    Indication: Polymyositis

Prednisone
    Dosage: 10mg daily

Prednisone
    Dosage: 17.5 mg/day
    Administration route: Oral

Prednisone
    Dosage: 60 mg/day

Prednisone
    Dosage: 2.5 mg/day



Possible Cyclophosphamide side effects in

Reported by a physician from Germany on 2012-08-20

Patient:

Reactions: Infection

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: unk
    Indication: Multiple Myeloma
    Start date: 2012-03-26
    End date: 2012-07-05

Dexamethasone
    Dosage: unk
    Indication: Multiple Myeloma
    Start date: 2012-03-26
    End date: 2012-07-05

Velcade
    Dosage: unk
    Indication: Multiple Myeloma
    Start date: 2012-03-26
    End date: 2012-07-05

Other drugs received by patient: Zometa; Amoxicillin



Possible Cyclophosphamide side effects in female

Reported by a physician from Sweden on 2012-08-20

Patient: female

Reactions: Nausea, Progressive Multifocal Leukoencephalopathy, Hepatic Enzyme Increased

Adverse event resulted in: death

Drug(s) suspected as cause:
Azathioprine
    Dosage: 150 mg/day
    Administration route: Oral
    Indication: Polymyositis

Cyclophosphamide
    Dosage: 100 mg/day
    Administration route: Oral
    Indication: Polymyositis

Methotrexate
    Dosage: 20 mg/week
    Indication: Polymyositis

Methylprednisolone

Prednisone
    Dosage: 40 mg/day
    Indication: Polymyositis

Prednisone
    Dosage: 2.5 mg/day

Prednisone
    Dosage: 10mg daily

Prednisone
    Dosage: 60 mg/day

Prednisone
    Dosage: 17.5 mg/day
    Administration route: Oral



Possible Cyclophosphamide side effects in male

Reported by a physician from Japan on 2012-08-18

Patient: male

Reactions: Drug Eruption, Pneumonia, Oral Candidiasis, Oral Herpes, Decreased Appetite

Adverse event resulted in: death

Drug(s) suspected as cause:
Actonel
    Administration route: Oral
    Start date: 2009-05-26
    End date: 2011-10-15

Aspirin
    Administration route: Oral
    Start date: 2006-12-22
    End date: 2011-10-15

Cyclophosphamide
    Administration route: Oral
    Start date: 2009-05-25
    End date: 2011-10-15

Cyclophosphamide
    Administration route: Oral
    Indication: Idiopathic Pulmonary Fibrosis
    Start date: 2006-12-22
    End date: 2007-03-19

Cyclophosphamide
    Administration route: Oral
    Start date: 2008-08-18
    End date: 2009-05-24

Cyclophosphamide
    Administration route: Oral
    Start date: 2007-03-20
    End date: 2008-08-17

Mucodyne
    Administration route: Oral
    Indication: Idiopathic Pulmonary Fibrosis
    Start date: 2007-04-17
    End date: 2011-10-15

Mucosolvan
    Administration route: Oral
    Indication: Idiopathic Pulmonary Fibrosis
    Start date: 2007-10-23
    End date: 2011-10-15

Pirfenidone
    Dosage: 400 mg/am, 400 mg/pm, 600 mg night
    Administration route: Oral
    Start date: 2009-12-14
    End date: 2010-07-07

Pirfenidone
    Dosage: 600 mg/am, 600 mg/pm, 400 mg night
    Administration route: Oral
    Start date: 2010-07-07
    End date: 2011-10-11

Pirfenidone
    Dosage: 200 mg/am, 200 mg/pm, 400 mg night
    Administration route: Oral
    Start date: 2009-11-30
    End date: 2009-12-14

Pirfenidone
    Administration route: Oral
    Indication: Idiopathic Pulmonary Fibrosis
    Start date: 2009-11-16
    End date: 2009-11-30

Povidone Iodine
    Start date: 2009-05-27
    End date: 2011-10-15

Prednisolone
    Administration route: Oral
    Indication: Idiopathic Pulmonary Fibrosis
    Start date: 2006-12-22
    End date: 2011-10-12

Prednisolone

Sulfamethoxazole and Trimethoprim
    Administration route: Oral
    Start date: 2007-03-21
    End date: 2011-10-15

Zolpidem
    Administration route: Oral
    Start date: 2007-01-23
    End date: 2011-10-15

Other drugs received by patient: Neoral; Flomox; Miconazole; Gentamicin Sulfate; Valtrex; Propeto; Neoral; Arasena-A; Olopatadine HCL; Hibidil; Myser



Possible Cyclophosphamide side effects in 37 year old male

Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-17

Patient: 37 year old male

Reactions: Graft Versus Host Disease

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: unk
    Indication: Bone Marrow Conditioning Regimen

Thymoglobulin
    Dosage: unk
    Indication: Bone Marrow Conditioning Regimen

Other drugs received by patient: Methotrexate; Cyclosporine



Possible Cyclophosphamide side effects in 68 year old male

Reported by a health professional (non-physician/pharmacist) from Spain on 2012-08-17

Patient: 68 year old male

Reactions: Hepatitis B

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Splenic Marginal Zone Lymphoma

Doxorubicin Hydrochloride
    Indication: Splenic Marginal Zone Lymphoma

Prednisone TAB
    Indication: Immunosuppression

Rituxan
    Indication: Splenic Marginal Zone Lymphoma

Vincristine
    Indication: Splenic Marginal Zone Lymphoma



Possible Cyclophosphamide side effects in 1 year old female

Reported by a physician from Japan on 2012-08-17

Patient: 1 year old female

Reactions: Graft Versus Host Disease

Adverse event resulted in: death

Drug(s) suspected as cause:
Busulfan
    Dosage: unk
    Indication: Bone Marrow Conditioning Regimen

Cyclophosphamide
    Dosage: unk
    Indication: Bone Marrow Conditioning Regimen

Thymoglobulin
    Dosage: unk
    Indication: Bone Marrow Conditioning Regimen

Other drugs received by patient: Methotrexate; Cyclosporine



Possible Cyclophosphamide side effects in 4 year old male

Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-17

Patient: 4 year old male

Reactions: Acute Graft Versus Host Disease

Adverse event resulted in: death

Drug(s) suspected as cause:
Busulfan
    Dosage: unk
    Indication: Bone Marrow Conditioning Regimen

Cyclophosphamide
    Dosage: unk
    Indication: Bone Marrow Conditioning Regimen

Thymoglobulin
    Dosage: unk
    Indication: Bone Marrow Conditioning Regimen

Other drugs received by patient: Methotrexate; Cyclosporine



Possible Cyclophosphamide side effects in male

Reported by a physician from Czech Republic on 2012-08-17

Patient: male, weighing 89.0 kg (195.8 pounds)

Reactions: Progressive Multifocal Leukoencephalopathy

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 500mg monthly
    Indication: Chronic Lymphocytic Leukaemia
    Start date: 2008-07-01
    End date: 2008-11-20

Fludarabine Phosphate
    Dosage: 50mg monthly
    Indication: Chronic Lymphocytic Leukaemia
    Start date: 2008-07-01
    End date: 2008-11-20

Ofatumumab
    Dosage: 1000mg monthly
    Indication: Chronic Lymphocytic Leukaemia
    Start date: 2008-06-30
    End date: 2008-11-18



Possible Cyclophosphamide side effects in female

Reported by a physician from Netherlands on 2012-08-16

Patient: female, weighing 7.4 kg (16.3 pounds)

Reactions: Capillary Leak Syndrome, Hepatic Function Abnormal, Respiratory Failure, Disease Progression, Ascites

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Clofarabine
    Dosage: 11 mg (40 mg/m2), qdx5
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2010-07-23
    End date: 2010-07-27

Cyclophosphamide
    Dosage: 80 mg, qd
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2010-07-23
    End date: 2010-07-27

Cytarabine
    Dosage: 15 mg, od
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2010-07-28
    End date: 2010-07-28

Cytarabine
    Indication: Chemotherapy

Etoposide
    Dosage: 28 mg, qd
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2010-07-23
    End date: 2010-07-27

Methotrexate
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: 6 mgr, od
    Indication: Chemotherapy
    Start date: 2010-07-28
    End date: 2010-07-28

Prednisolone
    Indication: Chemotherapy

Prednisolone
    Dosage: 6 mgr, od
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2010-07-28
    End date: 2010-07-28

Other drugs received by patient: Itraconazole; Vancomycin; Dexamethasone; Filgrastim; Teicoplanin; Ciprofloxacin HCL; Ciprofloxacin HCL; Tramadol HCL; Vancomycin; Ceftazidime; Zofran; Vancomycin; Furosemide; Cotrim; Vancomycin; Vitamin K TAB; Cotrim; Itraconazole; Vancomycin; Vancomycin; Omeprazole; Acetaminophen; Ciprofloxacin; Furosemide; Ceftazidime; Furosemide; Omeprazole



Possible Cyclophosphamide side effects in

Reported by a individual with unspecified qualification from France on 2012-08-16

Patient:

Reactions: Zygomycosis

Adverse event resulted in: death

Drug(s) suspected as cause:
Alemtuzumab

Cyclophosphamide

Fludarabine Phosphate



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017